Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
47,677,496
-
Total 13F shares
-
51,083,890
-
Share change
-
+1,778,475
-
Total reported value
-
$1,549,883,454
-
Put/Call ratio
-
65%
-
Price per share
-
$30.34
-
Number of holders
-
142
-
Value change
-
+$54,540,100
-
Number of buys
-
86
-
Number of sells
-
50
Institutional Holders of Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share (RAPP) as of Q4 2025
As of 31 Dec 2025,
Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share (RAPP) was held by
142 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
51,083,890 shares.
The largest 10 holders included
TRV GP V, LLC, FMR LLC, ARCH Venture Management, LLC, Capital International Investors, Cormorant Asset Management, LP, GOLDMAN SACHS GROUP INC, BlackRock, Inc., Sofinnova Investments, Inc., VANGUARD GROUP INC, and JOHNSON & JOHNSON.
This page lists
142
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.